# A Study to Evaluate the Effect of MK-5684 in Male Participants With Severe Renal Impairment (RI) and With End-stage Renal Disease (ESRD) (MK-5684-010)

> **NCT06814132** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 24 (actual)

## Conditions studied

- Kidney Failure, Chronic
- End-Stage Kidney Disease
- Renal Failure, Chronic
- Renal Failure, End-Stage
- Healthy Participants

## Interventions

- **DRUG:** MK-5684
- **DRUG:** Prednisone
- **DRUG:** Fludrocortisone acetate

## Key facts

- **NCT ID:** NCT06814132
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-04-07
- **Primary completion:** 2025-10-04
- **Final completion:** 2025-10-14
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2025-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06814132

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06814132, "A Study to Evaluate the Effect of MK-5684 in Male Participants With Severe Renal Impairment (RI) and With End-stage Renal Disease (ESRD) (MK-5684-010)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06814132. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*